Increases in Alpha 4*but Not Alpha 3*/alpha 6*nicotinic Receptor Sites and Function in the Primate Striatum Following Chronic Oral Nicotine Treatment

SE McCallum,N Parameswaran,T Bordia,H Fan,RF Tyndale,JW Langston,JM McIntosh,M Quik
DOI: https://doi.org/10.1111/j.1471-4159.2005.03646.x
2006-01-01
Journal of Neurochemistry
Abstract:Knowledge of the effects of chronic nicotine is critical considering its widespread use in tobacco products and smoking cessation therapies. Although nicotine is well known to up-regulate alpha 4* nAChR sites and function in the cortex, its actions in the striatum are uncertain because of the presence of multiple subtypes with potentially opposing effects. We therefore investigated the effect of long-term nicotine treatment on nAChR sites and function in the primate striatum, which offers the advantage of similar proportions of alpha 3*/alpha 6* and alpha 4* nAChRs. Nicotine was given in drinking water, which resembles smoking in its intermittent but chronic delivery. Plasma nicotine and cotinine levels were similar to smokers. Chronic nicotine treatment (> 6 months) enhanced alpha 4* nAChR-evoked [H-3]dopamine release in striatal subregions, with an overall pattern of increase throughout the striatum when normalized to uptake. This increase correlated with elevated striatal alpha 4* nAChRs. Under the same conditions, striatal alpha 3*/alpha 6* nAChR sites and function were decreased or unchanged. These divergent actions of chronic nicotine treatment on alpha 4* versus alpha 6* nAChRs, as well as effects on dopamine uptake, allow for a complex control of striatal activity to maintain dopaminergic function. Such knowledge is important for understanding nicotine dependence and the consequences of nicotine administration for the treatment of neurological disorders.
What problem does this paper attempt to address?